537 related articles for article (PubMed ID: 17364447)
1. The utility of levosimendan in the treatment of heart failure.
Lehtonen L; Põder P
Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
[TBL] [Abstract][Full Text] [Related]
2. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
4. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
Lehtonen L
Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
[TBL] [Abstract][Full Text] [Related]
5. Levosimendan: dual mechanisms for acute heart failure...and beyond?
Ng TM; Akhter MW
Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
8. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
Erhardt LR
Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367
[TBL] [Abstract][Full Text] [Related]
9. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
Cavana M; Pignataro C; Fraticelli A; Mebazaa A
Ital Heart J; 2003 May; 4 Suppl 2():61S-64S. PubMed ID: 14635372
[TBL] [Abstract][Full Text] [Related]
10. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
Mebazaa A; Erhardt L
Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
[TBL] [Abstract][Full Text] [Related]
11. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
Kivikko M; Lehtonen L
Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
[TBL] [Abstract][Full Text] [Related]
13. A promising new inotrope: levosimendan.
Fotbolcu H; Duman D
Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
[TBL] [Abstract][Full Text] [Related]
14. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
Nieminen MS; Sandell EP
Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
[TBL] [Abstract][Full Text] [Related]
15. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
Ponschab M; Hochmair N; Ghazwinian N; Mueller T; Plöchl W
Eur J Anaesthesiol; 2008 Aug; 25(8):627-33. PubMed ID: 18405408
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
Kota B; Prasad AS; Economides C; Singh BN
J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
Lehtonen L
Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan: a new approach for the treatment of patients with severe heart failure. A brief summary based on a clinical case.
Morais J; Dias B; Pontes N
Rev Port Cardiol; 2003; 22(7-8):941-8. PubMed ID: 14587161
[TBL] [Abstract][Full Text] [Related]
19. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
Graudins A; Najafi J; Rur-SC MP
Clin Toxicol (Phila); 2008 Jan; 46(1):50-6. PubMed ID: 17926153
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan: implications for clinicians.
McBride BF; White CM
J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
